← ANALYST RATINGS · TIPRANKS
Design Therapeutics (DSGN): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $26.11, the highest $40.54, the lowest $20.00. The average is +153.2% from the last price of $10.31.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $10.00 → $10.50+5.0% | Hold | +1.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.00 → $10.50+5.0% | Hold | +1.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.00 → $10.50+5.0% | Hold | +1.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $10.00 → $10.50+5.0% | Hold | +1.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $9.50 → $10.50+10.5% | Hold | +1.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.00 → $10.50+5.0% | Hold | +1.8% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| Unknown Analyst | Leerink Partners | $22.00 | Buy | +113.4% | Reiterated | 13.10.26on TipRanks Oct 15 05:05 | −10.3%next day +0.6% | ↗ |
| Name not given | — | $26.00 | Buy | +152.2% | Initiated | 12.10.26on TipRanks 09:06 | −6.3%next day −10.3% | ↗ |
| Unknown Analyst | Cantor Fitzgerald | $40.54 | Buy | +293.2% | Reiterated | 05.08.26on TipRanks 21:45 | +1.6%next day +1.0% · 5 days +3.3% | ↗ |
| Adam Vogel★★★★★★★★★★#1113 · hits 79% · avg +38.0% | Craig-Hallum | $22.00 | Buy | +113.4% | Reiterated | 04.08.26on TipRanks 09:43 | +1.6%next day +3.0% · 5 days +10.9% | ↗ |
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $20.00 | Buy | +94.0% | Reiterated | 03.08.26on TipRanks Aug 5 21:45 | +3.3%next day +1.6% · 5 days +10.3% | ↗ |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $21.00 | Buy | +103.7% | Reiterated | 15.06.26on TipRanks 07:50 | −0.2%next day −3.2% · 5 days +25.9% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $20.00 | Buy | +94.0% | Reiterated | 27.05.26on TipRanks 07:35 | −2.6%next day −3.8% · 5 days −6.4% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $10.01 → $15.00+49.9% | Buy | +45.5% | Initiated | 15.03.26on TipRanks 20:30 | +7.6%next day +0.2% · 5 days −5.7% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $14.00 | Buy | +35.8% | Upgrade | 03.12.25on TipRanks 07:55 | +8.9%next day +0.4% · 5 days −4.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Design Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $27.51 at a price of $12.57 (+118.9%); now: $26.11 at $10.31 (+153.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 4 | 3 | 6 |
| Buy | 6 | 4 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.34 (from $-0.36 to $-0.30). Last quarter: $-0.32.
Best top-analyst consensus in the sector · Healthcare
About Design Therapeutics
- CEO: Pratik Shah
- Employees: 55
- 6005 Hidden Valley Road, Carlsbad, CA, 92011, US
- www.designtx.com
Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.
Data from the stock’s TipRanks forecast page, read 71 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗